Alignment Healthcare Faces Investigation Over Accounting Irregularities

The scrutiny follows a July 8, 2026, disclosure involving a whistleblower complaint from a former executive. The complaint alleges that Alignment Healthcare improperly recorded millions of dollars in operating expenses as capital expenditures, a practice that artificially boosted the company's financial standing. Following the revelation, Alignment’s stock price plummeted 16.7%, shedding $4.02 per share to close at $20.03.

Pomerantz LLP is now spearheading an investigation into whether the company’s officers or directors engaged in unlawful business practices. Investors impacted by the stock’s decline are being urged to contact Danielle Peyton at the law firm to discuss potential participation in class action litigation. This inquiry examines the integrity of the firm's non-GAAP financial reporting, which remains a cornerstone of its investor communications.